Proteomics International Laboratories Ltd in collaboration with Janssen Research & Development have shown that treatment with Canagliflozin lowers the PromarkerD risk score for developing. | May 3, 2023
Proteomics International Laboratories Ltd (ASX:PIQ) in collaboration with Janssen Research & Development have shown that treatment with Canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide the following update on its business activities for the three months to 31 March 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has appointed additional members to its Clinical Advisory Board adding world leading healthcare professionals from the United States.
ASX-listed Proteomics International Laboratories has beefed up its clinical advisory board ahead of the rollout of its Promarker D predictive test for diabetic kidney disease in type 2 diabetes patients.